Survey finds lack of patient access to online records

Despite the increase in EHR adoption, more than half of patients cannot access their full health records electronically, according to a HealthMine survey.

The healthcare technology firm surveyed 502 U.S. consumers on their ability to access their health data online. Fifty-three percent said they can't access all their information and 74 percent said having easy electronic access to this information would improve their health knowledge and improve communication with their physicians.

Thirty percent said they have had trouble accessing their health data when they needed it, 32 percent have had difficulty accessing their record, 29 percent have had difficulty accessing their lab record and 25 percent have had difficulty accessing their prescription history.

"We should be long beyond the days where one doctor holds the chart and we don't get to see it—but we're not," said Bryce Williams, president and CEO of HealthMine, in a release. "Sitting in the driver's seat of health requires transparency of health data. Consumers must be able to see the road, the potholes, the landmarks. Having access to complete health information is essential to managing health and healthcare dollars—and every consumer should have it."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.